Rhabdomyosarcoma in children: Retrospective analysis from a single tertiary care center in Saudi Arabia. Issue 1 (9th August 2022)

• Record Type: Journal Article
• Authors: Markiz, Samer N.; Khan, Safia; Wagley, Zainab B.; Viqaruddin, Mohammed K.; Khafaga, Yasser M.; AlFawaz, Ibrahim A.; AlAnazi, Awatif E.; AlKofide, Amani; Khoja, Hatem A.; Ali, Afshan A.
• Is Part Of: Cancer reports. Volume 6:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-09
• Subjects: children cancer -- retrospective study -- rhabdomyosarcoma -- tertiary care; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1683
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children occurring most commonly in the head and neck region. The treatment involves using a multimodality approach including chemotherapy, surgery, and radiation therapy. Survival for patients with localized disease has improved markedly, but the treatment of advanced disease remains a challenge. We report the clinical characteristics and outcome for patients treated at a tertiary care center in Saudi Arabia. Methods: Patients aged 0–14 years diagnosed with RMS between 2005 and 2018 were included. Statistical analysis was performed using SPSS software. Kaplan–Meier method was used to calculate overall and event free survival. Cox proportional hazards model was used for multivariate analysis. Results: One hundred and twenty‐four patients were analyzed. The median age was 5.7 years with male predominance (2.4:1). The most common primary sites were head/neck (30%) and the genitourinary tract (25%). Embryonal RMS was present in 81%; alveolar in 19%. Most patients had intermediate risk disease (60%). The 5‐year overall and event free survivals were 64.3% and 53.3%, respectively. Survival was influenced by primary tumor site, histology, and clinical risk group. Unfavorable primary site, high risk stratification, and poor initial response to therapy predicted a poor outcome. Conclusion: This study provides an insight on the current management outcomes for our patients with RMS. Cytogenetics and molecular diagnostics need to be incorporated as standard of care in the therapeutic approach of our patients. In addition, there is a need for national collaborative efforts to improve the outcome of RMS in children and adolescents.